selpercatinib

News

FDA clears Lilly’s Retevmo for RET-positive lung, thyroid ca...

Eli Lilly now has a second approved drug from its takeover of Loxo Oncology last year after getting the go-ahead from the FDA for RET inhibitor Retevmo.

Oncology

Interview with Vicky Brown at Pharma USA 2026

Hernexeos and what’s next, with Vicky Brown

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

FDA clears Lilly’s Retevmo for RET-positive lung, thyroid ca...

Lilly keeps ahead of Blueprint with swift FDA review for sel...

Relief for Lilly as drug from $8bn Loxo deal clears pivotal ...

Hernexeos and what’s next, with Vicky Brown

Using AI-driven synthetic personas to take your insights fur...

Editor's Picks